RAPT Therapeutics Inc.

About RAPT Therapeutics Inc.

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immunologic diseases. Their mission is to transform the treatment of these conditions by targeting key drivers of the immune system, aiming to improve and empower countless lives.

Products & Services

RPT904:A long-acting anti-IgE antibody designed to make a difference in treating food allergies.

Specialties

Inflammatory Diseases Immunologic Diseases Anti-IgE Antibodies CCR4 in Inflammation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2025-10-21 FD: 2025-10-21	7 investors

Public Offering of Common Stock Latest

2025-10-21

$250.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Brian Wong

President and Chief Executive Officer

D

Dirk Brockstedt

Chief Scientific Officer

W

William Ho

Chief Medical Officer

R

Rodney Young

Chief Financial Officer

G

Gwen Carscadden

Chief Human Resources Officer

P

Paul Kassner

Senior Vice President, Biology

View 21 more team members with Pro

Unlock Full Team Directory

Recent News